Arnau Busquets-Garcia
Overview
Explore the profile of Arnau Busquets-Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Parra J, Barrera-Conde M, Kossatz E, Veza E, de la Torre R, Busquets-Garcia A, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2024 Nov;
136():111200.
PMID: 39571716
Sex differences in the composition and functionality of gut microbiota are an emerging field of interest in neurodevelopmental disorders, as they may help in understanding the phenotypic disparities between males...
2.
Gomez-Sotres P, Skupio U, Dalla Tor T, Julio-Kalajzic F, Cannich A, Gisquet D, et al.
Nat Commun
. 2024 Aug;
15(1):7103.
PMID: 39155299
Emotions and behavior can be affected by social chemosignals from conspecifics. For instance, olfactory signals from stressed individuals induce stress-like physiological and synaptic changes in naïve partners. Direct stress also ...
3.
Barrera-Conde M, Ramon-Duaso C, Gonzalez-Parra J, Veza-Estevez E, Chevaleyre V, Piskorowski R, et al.
Prog Neurobiol
. 2024 Jul;
240:102652.
PMID: 38955325
Psychotic disorders entail intricate conditions marked by disruptions in cognition, perception, emotions, and social behavior. Notably, psychotic patients who use cannabis tend to show less severe deficits in social behaviors,...
4.
Haney M, Vallee M, Fabre S, Collins Reed S, Zanese M, Campistron G, et al.
Nat Med
. 2023 Jun;
29(6):1487-1499.
PMID: 37291212
Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid...
5.
Skupio U, Welte J, Serrat R, Eraso-Pichot A, Julio-Kalajzic F, Gisquet D, et al.
Neuron
. 2023 Apr;
111(12):1887-1897.e6.
PMID: 37098353
Corticosteroid-mediated stress responses require the activation of complex brain circuits involving mitochondrial activity, but the underlying cellular and molecular mechanisms are scantly known. The endocannabinoid system is implicated in stress...
6.
Serrat R, Covelo A, Kouskoff V, Delcasso S, Ruiz-Calvo A, Chenouard N, et al.
Cell Rep
. 2022 Oct;
41(2):111499.
PMID: 36223755
No abstract available.
7.
Busquets-Garcia A, Bolanos J, Marsicano G
Nat Metab
. 2022 Jul;
4(7):848-855.
PMID: 35817852
No abstract available.
8.
Busquets-Garcia A, Holmes N
Front Behav Neurosci
. 2022 Jun;
16:928769.
PMID: 35711691
No abstract available.
9.
Vidal-Palencia L, Ramon-Duaso C, Gonzalez-Parra J, Busquets-Garcia A
Front Pharmacol
. 2022 Apr;
13:864591.
PMID: 35370697
Alzheimer's disease (AD) is the most common type of dementia and neurodegeneration. The actual cause of AD progression is still unknown and no curative treatment is available. Recently, findings in...
10.
Madrid-Gambin F, Gomez-Gomez A, Busquets-Garcia A, Haro N, Marco S, Mason N, et al.
Biomed Pharmacother
. 2022 Mar;
149:112845.
PMID: 35339828
There has been a renewed interest in the potential use of psychedelics for the treatment of psychiatric conditions. Nevertheless, little is known about the mechanism of action and molecular pathways...